ArriVent Biopharma: Truist Securities raises target price to $24 from $21
AVBP•Truist Securities raised its target price for ArriVent Biopharma to $24 from $21.
Related News
Qualys target price raised to $185 from $175 by Wedbush
QLYS•
Deutsche Bank raises Fortune Brands Innovations target price to $48 from $41
FBIN•
Adtran Networks Q3 2026 operating profit more than triples year on year to EUR 9.13 million
ADTN•
SABESP fiscal council backs R$ 2.64 billion interest on equity payout
SBS•
Fed to raise rates once more in December as inflation risks stay high
TLT•